Focus on cellular immunotherapy, the giant's emerging pharmaceutical companies: founded in 2016 by two major global pharmaceutical research and development companies, Juno and Wuxi Apptec, the company is the world's leading clinical cell therapy platform, establishing an integrated platform focused on the development, manufacture and commercialization of breakthrough cellular immunotherapy for blood cancer and solid tumors. The company is a pioneer in the development of cellular immunotherapy in China, ploughing the CAR-T track for many years, has a strong pharmaceutical research and development capability, the core candidate products are coming to market soon, and the potential pipeline products are rich.
The demand for tumor immunotherapy is growing rapidly, and the CAR-T track has great potential: as a new treatment, immunotherapy has a broad application prospect and the market is developing rapidly. According to data from Frost & Sullivan, China's immunotherapy market is about 1.9 billion yuan in 2018. With the launch of a number of blockbuster products, it is expected to reach 82.4 billion yuan in 2023 and further grow to 229.1 billion yuan in 2030. As a kind of cellular immunotherapy, CAR-T has been proved to have efficient tumor killing ability in the treatment of some hematological tumors, and it may make a greater breakthrough in the treatment of solid tumors in the future.
China's CAR-T market is expected to grow to 600 million yuan in 2021. Due to the increase in diagnosed cancer patients, increased affordability and a good regulatory environment, China's CAR-T market is expected to grow to 5.4 billion yuan in 2024 and 24.3 billion yuan in 2030, with a compound annual growth rate of 28.7 percent from 2024 to 2030.
CAR-T R & D pipeline is rich, Relma-cel is expected to become the best of its kind: the company has established a comprehensive and differentiated cellular immunotherapy product pipeline, covering hematological tumors and solid tumors and other indications, reasonable layout and development potential. As the first star product of the company, Relma-cel has shown certain advantages in clinical data, and the research and development is progressing smoothly, leading the way in China.
Investment suggestion: the company is a joint venture between Wuxi Apptec and Juno, with strong R & D strength, outstanding advantages in cellular immunotherapy, especially CAR-T track, in a leading position. As a revolutionary method of tumor therapy, immunotherapy has strong market potential and broad prospects. The company has established a research and development pipeline composed of a variety of cellular immunotherapy products, covering a number of indications such as hematological tumors and solid tumors, with reasonable layout. As the first star product of the company, Relma-cel has shown certain advantages in clinical data, and the research and development is progressing smoothly, leading the way in China. The company's other candidate products also have a certain market potential. With the continuous progress of R & D projects, the company is expected to make a further breakthrough in the field of CAR-T.
